Drug Discovery World
MARCH 2, 2023
AVA6000 is a pre|CISION tumour-targeted form of the established chemotherapy doxorubicin; designed to limit cell penetration of the drug — and therefore its cell killing effect — until it is specifically activated by fibroblast activation protein α (FAP), which is in high concentration in many solid tumours compared with healthy tissues.
Drug Discovery World
FEBRUARY 28, 2023
This presents a unique opportunity for mRNA-based therapies to potentially restore normal cell function by supplying copies of the functional transcript for the cell to read. mRNA enables the delivery of a transiently expressed genetic molecule that is translated into a target protein using the machinery of the host cell.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
APRIL 5, 2022
The technique uses artificial intelligence (AI) to analyse protein data harvested from tumour cells, using an algorithm trained by looking at changes to 52 proteins when they are exposed to a panel of targeted anticancer drugs. The post AI test could predict best cancer therapies for patients appeared first on.
Drug Discovery World
APRIL 21, 2023
Managing all of these elements using iterative design and prototyping can play a key role in successful project delivery, and marrying technologies with biochemical or cellular assays has the potential to bring disruptive change across fields as diverse as personalised medicine, diagnostics and drug screening.
Drug Discovery World
JUNE 14, 2023
Besides looking at donor characteristics, our platform, which we call Excellos 360TM, includes the assessment of metabolic and effector potential of cells, and genetic analysis. According to the spokesperson, blood donorship is hugely important for the development of new and potentially transformative macrophage cell therapies.
Expert insights. Personalized for you.
52 
Let's personalize your content